CME Presentations

Adult Epilepsy



  • Scott Perry, MD

    Scott Perry, MD

    Scott Perry, MD

    Head of Neurosciences

    M. Scott Perry, MD, is the medical director of Neurology and the Genetic Epilepsy Clinic, as well as co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Medical Center in Fort Worth, Texas. His clinical and research interests include the use of epilepsy surgery for the treatment of intractable childhood epilepsy and the evaluation and treatment of genetic epilepsy syndromes. Dr Perry completed his medical degree at the University of Mississippi School of Medicine in Jackson and general pediatrics and child neurology training at Emory University in Atlanta, Georgia. He completed a clinical neurophysiology fellowship at Miami Children’s Hospital before joining Cook Children’s in 2009.
  • Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)

    Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)

    Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)

    Professor of Medicine (Neurology)

    Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG), is the medical director of the Epilepsy Program at the University Health Network, University of Toronto, the founder and director of Krembil Neuroscience Epilepsy Genetics Program, and the director of the Epilepsy Transition Program, a program in collaboration with The Hospital for Sick Children that helps promote coordinated, smooth, and efficient transition from the pediatric to the adult health systems for patients with intractable epilepsy. She was the chair of the epilepsy implementation task force sub-group for the development of Guidelines for Transition in Epilepsy for the Province of Ontario. Dr Andrade received her medical degree from Universidade Federal do Parana (Brazil).

CME Information

Managing Adult Refractory Epilepsy Patients: Why it is important to consider genetic epilepsy syndromes

Global LogoPQH Logo


After completing this activity, the participant should be better able to:
  • Describe the disease burden experienced by adults with drug-resistant epilepsy and their caregivers
  • Explain the impact of incorrect diagnosis on treatment response
  • Define how new diagnostic approaches (including genetic testing) and management options have the potential to improve the outcomes of patients with developmental and epileptic encephalopathies (DEEs) such as Dravet syndrome
  • Discuss the implications of recent developments in the management of various DEEs in pediatric and adolescent patients and its potential impact on treating adults with refractory epilepsy
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.


This activity is supported by an educational grant from Zogenix, Inc.


This activity was released on October 16, 2020 and is valid for one year. Requests for credit must be made no later than October 16, 2021.


The educational design of this activity addresses the needs of pediatric and adult neurologists, epileptologists, pediatricians, pharmacists, and aligned specialists (RNs, NPs, PAs) involved in the treatment of patients with epilepsy.


Due to early mortality rates, Dravet syndrome is often considered a pediatric-only condition; in fact, about 80% of these patients will survive into adulthood and require lifelong care. In addition, a recent survey found that one-third of patients with Dravet syndrome were not correctly diagnosed until adulthood. Clinicians must have a higher index of suspicion for Dravet syndrome in their adult patients and recognize when to reconsider diagnoses in those with drug-resistant epilepsy. An improved understanding of the genetic underpinnings of Dravet syndrome has been instrumental in guiding diagnosis and treatment selection in children and may open doors for adult patients with intractable epilepsy moving forward.

Join us for this important educational activity, as Dr. M. Scott Perry and Dr. Danielle M. Andrade review the optimal care of adults with refractory epilepsy, along with key concepts related to Dravet syndrome. Learn when to consider genetic testing to help guide a precision-medicine approach, when to refer for a specialist evaluation, and how new treatments are providing renewed hope to some adult patients with intractable epilepsy.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates enduring live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
M. Scott Perry, MD
Medical Director, Neurology,
Co-Director, Jane and John Justin Neurosciences Center,
Director, Genetic Epilepsy Clinic,
Cook Children’s Medical Center
Consultant/Independent Contractor: Stoke: advisory board/consultant; Encoded: consultant/advisory board Grant/Research Support: Research support paid to Cook Children's from Stoke, Greenwich, Zogenix, Marinus, Ovid Speaker’s Bureau: Biocodex: speakers bureau Advisory Board: Zogenix: advisory board; Greenwich Biosciences: advisory board; Stoke: advisory board; Encoded: advisory board
Danielle Andrade, MD, MSc, FRCPC, CSCN (EEG)
Professor of Medicine (Neurology),
Medical Director, Epilepsy Program,
Director of Epilepsy Genetics Research Program,
Director, Epilepsy Transition Program,
University of Toronto
Honoraria: UCB Advisory Board: Stroke Therapeutics Royalty: UpToDate

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Elizabeth del Nido Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeruoSeriesLive at 877-394-1306 or at